FDA Brief

Warning letters Drugs

FDA warning letter to

inspire.clinic

LowIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.

What happened

FDA reviewed the website https://www.inspire.clinic in August 2025 and observed that it offers compounded semaglutide and tirzepatide drug products. FDA said website claims such as “similar to Ozempic,” “similar to Mounjaro,” and “comparable to Ozempic” are false or misleading because compounded drugs are not FDA-approved.

What FDA found

  1. The website claimed compounded semaglutide was “similar to Ozempic” and compounded tirzepatide was “similar to Mounjaro,” implying they are the same as FDA-approved drugs when compounded drugs are not FDA-approved.

    FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. The website claim that “5 mg of semaglutide [is] comparable to Ozempic” is false or misleading for the same reason.

    FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. Because the labeling and advertising were false or misleading, FDA says the compounded semaglutide and tirzepatide products are misbranded.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. FDA says introducing or delivering these misbranded drugs into interstate commerce is a prohibited act.

    FDCA § 301(a) [21 U.S.C. § 331(a)]
  5. FDA also says receiving, delivering, or offering delivery of misbranded drugs in interstate commerce is prohibited.

    FDCA § 301(c) [21 U.S.C. § 331(c)]

What FDA wants

Within 15 working days, provide a written response to CDER’s Office of Compounding Quality and Compliance describing steps taken to correct the violations and prevent recurrence, with supporting documents. FDA also says to take immediate action, including ceasing the misleading claims.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • compounding pharmacies and their marketing partners
  • regulatory teams reviewing drug promotional claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low